John R Perfect

List of Publications by Citations

252 papers	18,390 citations	59 h-index	134 g-index
280 ext. papers	21,963 ext. citations	7.1 avg, IF	6.86 L-index

#	Paper	IF	Citations
252	Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. *Clinical Infectious Diseases*, **2008**, 46, 1813-21	11.6	3744
251	Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. *Clinical Infectious Diseases*, **2010**, 50, 291-322	11.6	1683
250	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. *Clinical Infectious Diseases*, **2020**, 71, 1367-1376	11.6	607
249	**1998**,		592
248	Human dectin-1 deficiency and mucocutaneous fungal infections. *New England Journal of Medicine*, **2009**, 361, 1760-7	59.2	573
247	Voriconazole treatment for less-common, emerging, or refractory fungal infections. *Clinical Infectious Diseases*, **2003**, 36, 1122-31	11.6	562
246	Combination antifungal therapy. *Antimicrobial Agents and Chemotherapy*, **2004**, 48, 693-715	5.9	412
245	Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. *Clinical Infectious Diseases*, **2008**, 46, 120-8	11.6	395
244	Urease as a virulence factor in experimental cryptococcosis. *Infection and Immunity*, **2000**, 68, 443-8	3.7	395
243	Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. *Lancet Infectious Diseases, The*, **2016**, 16, 828-837	25.5	382
242	The antifungal pipeline: a reality check. *Nature Reviews Drug Discovery*, **2017**, 16, 603-616	64.1	360
241	Cryptococcosis. *Infectious Disease Clinics of North America*, **2002**, 16, 837-74, v-vi	6.5	314
240	Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. *Clinical Infectious Diseases*, **2008**, 47, 674-83	11.6	308
239	Cryptococcosis. *Infectious Disease Clinics of North America*, **2016**, 30, 179-206	6.5	302
238	Cyclic AMP-dependent protein kinase controls virulence of the fungal pathogen Cryptococcus neoformans. *Molecular and Cellular Biology*, **2001**, 21, 3179-91	4.8	288
237	Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans. *Molecular Microbiology*, **2001**, 39, 166-75	4.1	286
236	Analysis of the genome and transcriptome of Cryptococcus neoformans var. grubii reveals complex RNA expression and microevolution leading to virulence attenuation. *PLoS Genetics*, **2014**, 10, e1004261	6	260

235	Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. *Lancet Infectious Diseases, The*, **2021**, 21, e149-e162	25.5	242
234	RAS1 regulates filamentation, mating and growth at high temperature of Cryptococcus neoformans. *Molecular Microbiology*, **2000**, 36, 352-65	4.1	188
233	The Case for Adopting the "Species Complex" Nomenclature for the Etiologic Agents of Cryptococcosis. *MSphere*, **2017**, 2,	5	185
232	Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. *Antimicrobial Agents and Chemotherapy*, **2005**, 49, 952-8	5.9	182
231	CX3CR1-dependent renal macrophage survival promotes Candida control and host survival. *Journal of Clinical Investigation*, **2013**, 123, 5035-51	15.9	153
230	Morphologic criteria for the preliminary identification of Fusarium, Paecilomyces, and Acremonium species by histopathology. *American Journal of Clinical Pathology*, **1998**, 109, 45-54	1.9	150
229	Cryptococcosis diagnosis and treatment: What do we know now. *Fungal Genetics and Biology*, **2015**, 78, 49-54	3.9	145
228	Identification and characterization of a highly conserved calcineurin binding protein, CBP1/calcipressin, in Cryptococcus neoformans. *EMBO Journal*, **2000**, 19, 3618-29	13	136
227	Plasminogen alleles influence susceptibility to invasive aspergillosis. *PLoS Genetics*, **2008**, 4, e1000101	6	131
226	Protection against cryptococcosis by using a murine gamma interferon-producing Cryptococcus neoformans strain. *Infection and Immunity*, **2007**, 75, 1453-62	3.7	126
225	Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses. *Clinical Infectious Diseases*, **2016**, 63, 356-62	11.6	125
224	Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative/non-transplant. *PLoS ONE*, **2012**, 7, e43582	3.7	122
223	Characterization and regulation of the trehalose synthesis pathway and its importance in the pathogenicity of Cryptococcus neoformans. *Infection and Immunity*, **2006**, 74, 5877-87	3.7	120
222	Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. *Clinical Infectious Diseases*, **2005**, 40 Suppl 6, S401-8	11.6	120
221	Functional genomics identifies type I interferon pathway as central for host defense against Candida albicans. *Nature Communications*, **2013**, 4, 1342	17.4	119
220	Metabolic adaptation in Cryptococcus neoformans during early murine pulmonary infection. *Molecular Microbiology*, **2008**, 69, 1456-75	4.1	118
219	The STE12alpha homolog is required for haploid filamentation but largely dispensable for mating and virulence in Cryptococcus neoformans. *Genetics*, **1999**, 153, 1601-15	4	115
218	Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches. *Drugs*, **1997**, 54, 657-78	12.1	113

217	Azole antifungals: 35 years of invasive fungal infection management. *Expert Review of Anti-Infective Therapy*, **2015**, 13, 787-98	5.5	111
216	Novel Agents and Drug Targets to Meet the Challenges of Resistant Fungi. *Journal of Infectious Diseases*, **2017**, 216, S474-S483	7	103
215	Toll-like receptor 1 polymorphisms increase susceptibility to candidemia. *Journal of Infectious Diseases*, **2012**, 205, 934-43	7	102
214	Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 5758-65	5.9	92
213	Fungi that Infect Humans. *Microbiology Spectrum*, **2017**, 5,	8.9	87
212	Cryptococcosis. *Infectious Disease Clinics of North America*, **1989**, 3, 77-102	6.5	86
211	Population genomics and the evolution of virulence in the fungal pathogen. *Genome Research*, **2017**, 27, 1207-1219	9.7	85
210	The Cryptococcus neoformans transcriptome at the site of human meningitis. *MBio*, **2014**, 5, e01087-13	7.8	85
209	Trehalose 6-phosphate phosphatase is required for cell wall integrity and fungal virulence but not trehalose biosynthesis in the human fungal pathogen Aspergillus fumigatus. *Molecular Microbiology*, **2010**, 77, 891-911	4.1	85
208	Cryptococcus neoformans: a sugar-coated killer with designer genes. *FEMS Immunology and Medical Microbiology*, **2005**, 45, 395-404		82
207	Identification and characterization of the Cryptococcus neoformans phosphomannose isomerase-encoding gene, MAN1, and its impact on pathogenicity. *Molecular Microbiology*, **2001**, 40, 610-20	4.1	80
206	2112. Voriconazole for Primary Prophylaxis: A Decade of Trends and Outcomes. *Open Forum Infectious Diseases*, **2019**, 6, S715-S715	1	78
205	The trehalose synthesis pathway is an integral part of the virulence composite for Cryptococcus gattii. *Infection and Immunity*, **2009**, 77, 4584-96	3.7	75
204	Fungal diagnosis: how do we do it and can we do better?. *Current Medical Research and Opinion*, **2013**, 29 Suppl 4, 3-11	2.5	72
203	Drug resistance in Cryptococcus neoformans. *Drug Resistance Updates*, **1999**, 2, 259-269	23.2	72
202	Cryptococcus neoformans requires a functional glycolytic pathway for disease but not persistence in the host. *MBio*, **2011**, 2, e00103-11	7.8	71
201	Titan cells formation in Cryptococcus neoformans is finely tuned by environmental conditions and modulated by positive and negative genetic regulators. *PLoS Pathogens*, **2018**, 14, e1006982	7.6	65
200	The impact of the host on fungal infections. *American Journal of Medicine*, **2012**, 125, S39-51	2.4	64

199	Use of Antifungal Combination Therapy: Agents, Order, and Timing. *Current Fungal Infection Reports*, **2010**, 4, 87-95	1.4	63
198	Immunochip SNP array identifies novel genetic variants conferring susceptibility to candidaemia. *Nature Communications*, **2014**, 5, 4675	17.4	62
197	Topoisomerase I is essential in Cryptococcus neoformans: role In pathobiology and as an antifungal target. *Genetics*, **1999**, 152, 167-78	4	62
196	Cytokine gene polymorphisms and the outcome of invasive candidiasis: a prospective cohort study. *Clinical Infectious Diseases*, **2012**, 54, 502-10	11.6	61
195	Association of plasma levels of human immunodeficiency virus type 1 RNA and oropharyngeal Candida colonization. *Journal of Infectious Diseases*, **1999**, 180, 534-7	7	59
194	Intracellular Action of a Secreted Peptide Required for Fungal Virulence. *Cell Host and Microbe*, **2016**, 19, 849-64	23.4	59
193	and Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	58
192	Tracing Genetic Exchange and Biogeography of var. at the Global Population Level. *Genetics*, **2017**, 207, 327-346	4	57
191	Adverse drug reactions to systemic antifungals. Prevention and management. *Drug Safety*, **1992**, 7, 323-63	5.1	55
190	Brain inositol is a novel stimulator for promoting Cryptococcus penetration of the blood-brain barrier. *PLoS Pathogens*, **2013**, 9, e1003247	7.6	54
189	Central Role of the Trehalose Biosynthesis Pathway in the Pathogenesis of Human Fungal Infections: Opportunities and Challenges for Therapeutic Development. *Microbiology and Molecular Biology Reviews*, **2017**, 81,	13.2	51
188	Live Imaging of Host-Parasite Interactions in a Zebrafish Infection Model Reveals Cryptococcal Determinants of Virulence and Central Nervous System Invasion. *MBio*, **2015**, 6, e01425-15	7.8	49
187	Invasive Fungal Infection After Lung Transplantation: Epidemiology in the Setting of Antifungal Prophylaxis. *Clinical Infectious Diseases*, **2020**, 70, 30-39	11.6	48
186	ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries. *Mycoses*, **2021**, 64, 1028-1037	5.2	48
185	CXCR1-mediated neutrophil degranulation and fungal killing promote Candida clearance and host survival. *Science Translational Medicine*, **2016**, 8, 322ra10	17.5	47
184	The RIG-I-like helicase receptor MDA5 (IFIH1) is involved in the host defense against Candida infections. *European Journal of Clinical Microbiology and Infectious Diseases*, **2015**, 34, 963-974	5.3	46
183	Microevolution of Serial Clinical Isolates of var. and. *MBio*, **2017**, 8,	7.8	44
182	Posaconazole exhibits in vitro and in vivo synergistic antifungal activity with caspofungin or FK506 against Candida albicans. *PLoS ONE*, **2013**, 8, e57672	3.7	43

181	Survival defects of Cryptococcus neoformans mutants exposed to human cerebrospinal fluid result in attenuated virulence in an experimental model of meningitis. *Infection and Immunity*, **2010**, 78, 4213-25	3.7	43
180	Antisense repression in Cryptococcus neoformans as a laboratory tool and potential antifungal strategy. *Microbiology (United Kingdom)*, **2002**, 148, 213-219	2.9	43
179	Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations. *Expert Opinion on Emerging Drugs*, **2011**, 16, 559-586	3.7	42
178	Disseminated Cryptococcosis With Brain Involvement in Patients With Chronic Lymphoid Malignancies on Ibrutinib. *Open Forum Infectious Diseases*, **2017**, 4, ofw261	1	40
177	Update on epidemiology of and preventive strategies for invasive fungal infections in cancer patients. *Clinical Infectious Diseases*, **2014**, 59 Suppl 5, S352-5	11.6	40
176	Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium. *Journal of Infectious Diseases*, **2020**, 222, S175-S198	7	39
175	Comparative analyses of clinical and environmental populations of Cryptococcus neoformans in Botswana. *Molecular Ecology*, **2015**, 24, 3559-71	5.7	38
174	Structures of trehalose-6-phosphate phosphatase from pathogenic fungi reveal the mechanisms of substrate recognition and catalysis. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 7148-53	11.5	37
173	The war on cryptococcosis: A Review of the antifungal arsenal. *Memorias Do Instituto Oswaldo Cruz*, **2018**, 113, e170391	2.6	37
172	Performance of the T2Bacteria Panel for Diagnosing Bloodstream Infections: A Diagnostic Accuracy Study. *Annals of Internal Medicine*, **2019**, 170, 845-852	8	35
171	Trehalose pathway as an antifungal target. *Virulence*, **2017**, 8, 143-149	4.7	34
170	Blood gene expression signatures predict invasive candidiasis. *Science Translational Medicine*, **2010**, 2, 21ra17	17.5	34
169	The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries.. *Lancet Microbe, The*, **2022**,	22.2	34
168	Fatty acid synthesis is essential for survival of Cryptococcus neoformans and a potential fungicidal target. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 3537-45	5.9	33
167	Regulation of cytochrome c oxidase subunit 1 (COX1) expression in Cryptococcus neoformans by temperature and host environment. *Microbiology (United Kingdom)*, **2003**, 149, 1041-1049	2.9	32
166	Inkjet Printing of Amphotericin B onto Biodegradable Microneedles Using Piezoelectric Inkjet Printing. *Jom*, **2013**, 65, 525-533	2.1	31
165	Surfactant protein D facilitates Cryptococcus neoformans infection. *Infection and Immunity*, **2012**, 80, 2444-53	3.7	31
164	Tolerability profile of the current antifungal armoury. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, i26-i32	5.1	30

163	Human genetic susceptibility to Candida infections. *Medical Mycology*, **2012**, 50, 785-94	3.9	30
162	Present and Future Therapy of Infections. *Journal of Fungi (Basel, Switzerland)*, **2018**, 4,	5.6	27
161	Next generation multilocus sequence typing (NGMLST) and the analytical software program MLSTEZ enable efficient, cost-effective, high-throughput, multilocus sequencing typing. *Fungal Genetics and Biology*, **2015**, 75, 64-71	3.9	27
160	Isavuconazole for treatment of rare invasive fungal diseases. *Mycoses*, **2018**, 61, 518-533	5.2	26
159	Design of aerosolized amphotericin b formulations for prophylaxis trials among lung transplant recipients. *Clinical Infectious Diseases*, **2004**, 39 Suppl 4, S207-10	11.6	26
158	Genetic Susceptibility to Fungal Infections: What is in the Genes?. *Current Clinical Microbiology Reports*, **2016**, 3, 81-91	3.1	26
157	Prevalence, healthcare resource utilization and overall burden of fungal meningitis in the United States. *Journal of Medical Microbiology*, **2018**, 67, 215-227	3.2	26
156	Copy number variation contributes to cryptic genetic variation in outbreak lineages of Cryptococcus gattii from the North American Pacific Northwest. *BMC Genomics*, **2016**, 17, 700	4.5	25
155	Taming Amphotericin B. *Bioconjugate Chemistry*, **2015**, 26, 2021-4	6.3	24
154	Invasive mycoses: evolving challenges and opportunities in antifungal therapy (multimedia activity). *American Journal of Medicine*, **2011**, 124, S2-3	2.4	24
153	Phenotypic Variability Correlates with Clinical Outcome in Isolates Obtained from Botswanan HIV/AIDS Patients. *MBio*, **2018**, 9,	7.8	24
152	The Zinc Finger Protein Mig1 Regulates Mitochondrial Function and Azole Drug Susceptibility in the Pathogenic Fungus Cryptococcus neoformans. *MSphere*, **2016**, 1,	5	23
151	Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. *Cell*, **2021**, 184, 2955-2972.e25	56.2	22
150	Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance. *MBio*, **2019**, 10,	7.8	22
149	AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial. *Trials*, **2015**, 16, 276	2.8	21
148	The triple threat of cryptococcosis: it's the body site, the strain, and/or the host. *MBio*, **2012**, 3,	7.8	21
147	Deferoxamine treatment as a risk factor for zygomycete infection. *Journal of Infectious Diseases*, **1989**, 159, 151-2	7	21
146	Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species. *Mycoses*, **2018**, 61, 485-497	5.2	20

145	Novel Treatment of Cryptococcal Meningitis via Neurapheresis Therapy. *Journal of Infectious Diseases*, **2018**, 218, 1147-1154	7	20
144	Genome-wide analysis of the regulation of Cu metabolism in Cryptococcus neoformans. *Molecular Microbiology*, **2018**, 108, 473-494	4.1	19
143	How Clean Is the Linen at My Hospital? The Mucorales on Unclean Linen Discovery Study of Large United States Transplant and Cancer Centers. *Clinical Infectious Diseases*, **2019**, 68, 850-853	11.6	19
142	Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	18
141	Combination Therapy for Invasive Fungal Infections. *Current Fungal Infection Reports*, **2020**, 14, 40-49	1.4	17
140	Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial. *Mycoses*, **2018**, 61, 420-429	5.2	17
139	An integrative genomics approach identifies novel pathways that influence candidaemia susceptibility. *PLoS ONE*, **2017**, 12, e0180824	3.7	17
138	Genotypic diversity and clinical outcome of cryptococcosis in renal transplant recipients in Brazil. *Emerging Microbes and Infections*, **2019**, 8, 119-129	18.9	16
137	Fungal infections of the bones and joints. *Current Infectious Disease Reports*, **2001**, 3, 450-460	3.9	16
136	Repeated therapeutic lumbar punctures in cryptococcal meningitis - necessity and/or opportunity?. *Current Opinion in Infectious Diseases*, **2016**, 29, 539-545	5.4	16
135	Molecular Typing of the Cryptococcus neoformans/Cryptococcus gattii Species Complex **2014**, 327-357		15
134	New potential targets for antifungal development. *Expert Opinion on Therapeutic Targets*, **2000**, 4, 265-296		15
133	Environmental Niches for Cryptococcus neoformans and Cryptococcus gattii235-259		15
132	Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM. *Lancet Infectious Diseases, The*, **2021**, 21, e375-e386	25.5	15
131	Structural and Studies on Trehalose-6-Phosphate Synthase from Pathogenic Fungi Provide Insights into Its Catalytic Mechanism, Biological Necessity, and Potential for Novel Antifungal Drug Design. *MBio*, **2017**, 8,	7.8	14
130	Associations between Genotypes, Phenotypes, and Clinical Parameters of Human Disease: A Review. *Journal of Fungi (Basel, Switzerland)*, **2021**, 7,	5.6	14
129	Cases of disseminated cryptococcosis in intravenous drug abusers without HIV infection: A new risk factor?. *Medical Mycology Case Reports*, **2016**, 14, 17-19	1.7	14
128	Cryptococcal Antigen in Serum and Cerebrospinal Fluid for Detecting Cryptococcal Meningitis in Adults Living With Human Immunodeficiency Virus: Systematic Review and Meta-Analysis of Diagnostic Test Accuracy Studies. *Clinical Infectious Diseases*, **2021**, 72, 1268-1278	11.6	14

127	A Genome-Wide Functional Genomics Approach Identifies Susceptibility Pathways to Fungal Bloodstream Infection in Humans. *Journal of Infectious Diseases*, **2019**, 220, 862-872	7	13
126	Cryptococcus neoformans resists to drastic conditions by switching to viable but non-culturable cell phenotype. *PLoS Pathogens*, **2019**, 15, e1007945	7.6	13
125	Cryptococcal meningitis with normal cerebrospinal fluid. *Journal of Infectious Diseases*, **1989**, 160, 912	7	13
124	Clinical Perspectives on Cryptococcus neoformans and Cryptococcus gattii: Implications for Diagnosis and Management595-606		13
123	Superiority of a Novel Mp1p Antigen Detection Enzyme Immunoassay Compared to Standard BACTEC Blood Culture in the Diagnosis of Talaromycosis. *Clinical Infectious Diseases*, **2021**, 73, e330-e336	11.6	12
122	The current treatment landscape: other fungal diseases (cryptococcosis, fusariosis and mucormycosis). *Journal of Antimicrobial Chemotherapy*, **2016**, 71, ii31-ii36	5.1	12
121	Landscape of gene expression variation of natural isolates of in response to biologically relevant stresses. *Microbial Genomics*, **2020**, 6,	4.4	12
120	Systematics of the Genus Cryptococcus and Its Type Species C. neoformans1-15		11
119	Human Cryptococcosis407-456		10
118	Comparing outcomes of early, late, and non-surgical management of intraspinal abscess. *Journal of Clinical Neuroscience*, **2017**, 36, 64-71	2.2	9
117	Very low levels of 25-hydroxyvitamin D are not associated with immunologic changes or clinical outcome in South African patients with HIV-associated cryptococcal meningitis. *Clinical Infectious Diseases*, **2014**, 59, 493-500	11.6	9
116	Ecology of Cryptococcus neoformans41-70		9
115	Emerging Issues in Antifungal Resistance. *Infectious Disease Clinics of North America*, **2020**, 34, 921-943	6.5	9
114	The robust and rapid role of molecular testing in precision fungal diagnostics: A case report. *Medical Mycology Case Reports*, **2020**, 27, 77-80	1.7	8
113	Management of cryptococcosis: how are we doing?. *PLoS Medicine*, **2007**, 4, e47	11.6	8
112	Emergence of the Molds Other than Aspergillus in Immunocompromised Patients. *Clinics in Chest Medicine*, **2017**, 38, 555-573	5.3	7
111	Scedosporium apiosermum infection of the "Native" valve: Fungal endocarditis in an orthotopic heart transplant recipient. *Medical Mycology Case Reports*, **2015**, 9, 34-6	1.7	7
110	Fungal Molecular Pathogenesis: What Can It Do and Why Do We Need It?1-11		7

109	Veterinary Insights into Cryptococcosis Caused by Cryptococcus neoformans and Cryptococcus gattii489-504		7
108	Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	6
107	Simple Strategy for Taming Membrane-Disrupting Antibiotics. *Bioconjugate Chemistry*, **2016**, 27, 2850-2853	5.9	6
106	Potential value of cefoperazone in bacterial meningitis: experimental studies. *Drugs*, **1981**, 22 Suppl 1, 60-4	12.1	6
105	Cryptococcus neoformans : a Sugar-Coated Killer279-303		6
104	The Mating-Type Locus of Cryptococcus: Evolution of Gene Clusters Governing Sex Determination and Sexual Reproduction from the Phylogenomic Perspective139-149		6
103	The Architecture and Antigenic Composition of the Polysaccharide Capsule43-54		6
102	Diagnosis and Laboratory Techniques381-405		6
101	Virulence Factors145-176		6
100	Efficacy of Oral APX001 in a Murine Model of Cryptococcal Meningitis. *Open Forum Infectious Diseases*, **2017**, 4, S478-S478	1	5
99	Mycobacterium avium-intracellulare complex infections in the acquired immunodeficiency syndrome. *Journal of Electron Microscopy Technique*, **1988**, 8, 105-13		5
98	The History of Cryptococcus and Cryptococcosis17-26		5
97	Invasion of Cryptococcus into the Central Nervous System465-471		5
96	Diagnostic Approach Based on Capsular Antigen, Capsule Detection, Glucan, and DNA Analysis547-564		5
95	Population Structure and Ecology of Cryptococcus neoformans and Cryptococcus gattii97-111		5
94	A case of CNS aspergillosis in a patient with chronic lymphocytic leukemia on first-line ibrutinib therapy. *Medical Mycology Case Reports*, **2020**, 27, 17-21	1.7	5
93	Occult Infection Unveiled by the Novel Mp1p Antigen Detection Assay. *Open Forum Infectious Diseases*, **2020**, 7, ofaa502	1	5
92	MSG07: An International Cohort Study Comparing Epidemiology and Outcomes of Patients With Cryptococcus neoformans or Cryptococcus gattii Infections. *Clinical Infectious Diseases*, **2021**, 73, 1133-1141	11.6	5

91	Cryptococcal meningoencephalitis: time for action. *Lancet Infectious Diseases, The*, **2021**, 21, e259-e271	25.5	5
90	Antifungal resistance: the clinical front. *Oncology*, **2004**, 18, 15-22	1.8	5
89	The virulence factor urease and its unexplored role in the metabolism of Cryptococcus neoformans. *FEMS Yeast Research*, **2020**, 20,	3.1	4
88	Assessing the virulence of Cryptococcus neoformans causing meningitis in HIV infected and uninfected patients in Vietnam. *Medical Mycology*, **2020**, 58, 1149-1161	3.9	4
87	Pulmonary blastomycosis presenting as primary lung cancer. *BMC Infectious Diseases*, **2018**, 18, 336	4	4
86	Cryptococcosis in AIDS515-525		4
85	Public Health Importance of Cryptococcal Disease: Epidemiology, Burden, and Control585-593		4
84	A global call for talaromycosis to be recognised as a neglected tropical disease. *The Lancet Global Health*, **2021**, 9, e1618-e1622	13.6	4
83	Drug Resistance in Cryptococcosis **2017**, 1119-1140		4
82	The longitudinal health economic impact of viral encephalitis in the United States. *Journal of Medical Microbiology*, **2020**, 69, 270-279	3.2	4
81	Fab-dimerized glycan-reactive antibodies neutralize HIV and are prevalent in humans and rhesus macaques		4
80	Amoeba Predation of Cryptococcus neoformans Results in Pleiotropic Changes to Traits Associated with Virulence. *MBio*, **2021**, 12,	7.8	4
79	Familial Adenomatous Polyposis Manifesting as Endocarditis: A Case Report and Review of the Association of with Underlying Gastrointestinal Disease. *Case Reports in Infectious Diseases*, **2016**, 2016, 5805326	0.9	4
78	Real-world implications of QT prolongation in patients receiving voriconazole and amiodarone. *Journal of Antimicrobial Chemotherapy*, **2019**, 74, 228-233	5.1	4
77	Feasibility of Neurapheresis as a Therapy for Multidrug Resistant Gram-negative Bacterial Meningitis. *Open Forum Infectious Diseases*, **2017**, 4, S480-S481	1	3
76	Fungi that Infect Humans **2017**, 811-843		3
75	Cryptococcosis in Africa269-285		3
74	The Emergence of Cryptococcus gattii Infections on Vancouver Island and Expansion in the Pacific Northwest313-325		3

73	The Cell Wall of Cryptococcus67-79		3
72	Therapy of Cryptococcosis457-518		3
71	Specific Immunity and Cytokines223-269		3
70	Gene Expression of Diverse Cryptococcus Isolates during Infection of the Human Central Nervous System. *MBio*, **2021**, e0231321	7.8	3
69	A Novel Therapeutic Approach for Cryptococcal Meningitis. *Open Forum Infectious Diseases*, **2016**, 3,	1	3
68	Population Pharmacodynamics of Amphotericin B Deoxycholate for Disseminated Infection Caused by. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	3
67	In Vitro Characterization of the Neurapheresis System for the Treatment of Cryptococcal Meningitis. *Open Forum Infectious Diseases*, **2017**, 4, S481-S481	1	2
66	On-demand release of Candida albicans biofilms from urinary catheters by mechanical surface deformation. *Biofouling*, **2018**, 34, 595-604	3.3	2
65	Efficient, Cost-Effective, High-Throughput, Multilocus Sequencing Typing (MLST) Method, NGMLST, and the Analytical Software Program MLSTEZ. *Methods in Molecular Biology*, **2017**, 1492, 197-202	1.4	2
64	Posaconazole. *Drugs*, **2005**, 65, 1568-1569	12.1	2
63	A Role for Mating in Cryptococcal Virulence167-174		2
62	Drug Resistance in Cryptococcus: Epidemiology and Molecular Mechanisms203-216		2
61	Cryptococcosis in Asia287-297		2
60	Hybridization and Its Importance in the Cryptococcus Species Complex359-370		2
59	Biosynthesis and Genetics of the Cryptococcus Capsule27-41		2
58	Introduction to the Pathogen1-27		2
57	Prevention of Human Infection519-530		2
56	Population genomics ofCryptococcus neoformansvar.grubiireveals new biogeographic relationships and finely maps hybridization		2

55	Titan cells formation inCryptococcus neoformansis finely tuned by environmental conditions and modulated by positive and negative genetic regulators		2
54	Regulatory Mechanism of the Atypical AP-1-Like Transcription Factor Yap1 in Cryptococcus neoformans. *MSphere*, **2019**, 4,	5	2
53	1758. Epidemiology of Invasive Mycoplasma and Ureaplasma Infections Early after Lung Transplantation. *Open Forum Infectious Diseases*, **2019**, 6, S646-S646	1	2
52	Uncommon Yeasts and Molds Causing Human Disease **2021**, 813-834		2
51	Genomic characterization of recurrent mold infections in thoracic transplant recipients. *Transplant Infectious Disease*, **2018**, 20, e12935	2.7	2
50	Comparison of / Species Complex to Related Genera (and) Reveal Variances in Virulence Associated Factors and Antifungal Susceptibility. *Frontiers in Cellular and Infection Microbiology*, **2021**, 11, 642658	5.9	2
49	Management of invasive mycoses in hematology patients: current approaches. *Oncology*, **2004**, 18, 5-14	1.8	2
48	What Can the Clinical Mycology Laboratory Do for Clinicians Today and Tomorrow?. *Current Clinical Microbiology Reports*, **2017**, 4, 96-105	3.1	1
47	Clinical mycology today: A synopsis of the mycoses study group education and research consortium (MSGERC) second biennial meeting, September 27-30, 2018, Big Sky, Montana, a proposed global research agenda. *Medical Mycology*, **2020**, 58, 569-578	3.9	1
46	Black mold takes hold and story told. *Medical Mycology Case Reports*, **2020**, 29, 12-14	1.7	1
45	Complete Genome Sequences for Two Clinical Isolates from Northern and Southern Vietnam. *Microbiology Resource Announcements*, **2020**, 9,	1.3	1
44	Invasive Fungal Disease in the Transplant Population: An Overview **2019**, 519-541		1
43	Reply to Arg□lles. *Virulence*, **2017**, 8, 239	4.7	1
42	Curious Crosses: Injection-Induced Lesions. *American Journal of Medicine*, **2017**, 130, 31-33	2.4	1
41	QTc Prolongation in Patients Receiving Triazoles and Amiodarone. *Open Forum Infectious Diseases*, **2017**, 4, S84-S84	1	1
40	IRIS and Fungal Infections: What Have We Learned?. *Current Fungal Infection Reports*, **2012**, 6, 1-10	1.4	1
39	Sensing Extracellular Signals in Cryptococcus neoformans175-187		1
38	Signaling Cascades and Enzymes as Cryptococcus Virulence Factors217-234		1

37	Sexual Reproduction of Cryptococcus gattii: a Population Genetics Perspective299-311		1
36	Cryptococcus Interactions with Innate Cytotoxic Lymphocytes417-427		1
35	Cryptococcosis in Experimental Animals: Lessons Learned473-488		1
34	Cryptococcosis in Transplant Recipients505-514		1
33	Vaccines and Antibody Therapies from Cryptococcus neoformans to Melanoma537-546		1
32	Melanin: Structure, Function, and Biosynthesis in Cryptococcus55-66		1
31	Sexual Reproduction of Cryptococcus81-96		1
30	Antifungal pharmacotherapy for invasive mould infections		1
29	Inositol Metabolism Regulates Capsule Structure and Virulence in the Human Pathogen Cryptococcus neoformans. *MBio*, **2021**, e0279021	7.8	1
28	A randomized, double-blind, placebo-controlled clinical trial of fluconazole as early empiric treatment of coccidioidomycosis pneumonia (Valley Fever) in adults presenting with community-acquired pneumonia in endemic areas (FLEET-Valley Fever). *Contemporary Clinical Trials Communications*, **2021**, 24, 100851	1.8	1
27	Phenotypic variability correlates with clinical outcome inCryptococcusisolates obtained from Botswanan HIV/AIDS patients		1
26	Animal Models and Veterinary Aspects of Cryptococcosis325-350		1
25	Intracellular Replication and Exit Strategies441-450		1
24	Population genomics and the evolution of virulence in the fungal pathogenCryptococcus neoformans		1
23	Reply to Day et al. *Journal of Infectious Diseases*, **2021**, 224, 1627-1628	7	1
22	Paediatric bacterial meningitis in the USA: outcomes and healthcare resource utilization of nosocomial versus community-acquired infection. *Journal of Medical Microbiology*, **2021**, 70,	3.2	1
21	Use of newer antifungal therapies in clinical practice: what do the data tell us?. *Oncology*, **2004**, 18, 15-23	1.8	1
20	Cost-Effectiveness of Posaconazole Versus Standard Azole Therapy in the Prevention of Invasive Fungal Infections among High-Risk Neutropenic Patients in the U.S.. *Blood*, **2006**, 108, 3311-3311	2.2	0

19	Aortic Pseudoaneurysm Following Aortic Valve Replacement: Case Report and Review of the Literature.. *Open Forum Infectious Diseases*, **2021**, 8, ofab536	1	0
18	Outcomes and Health Care Resource Utilization of Adult Bacterial Meningitis in the United States. *Neurology: Clinical Practice*, **2021**, 11, 117-126	1.7	0
17	Transcriptional Profiles Elucidate Differential Host Responses to Infection with Cryptococcus neoformans and Cryptococcus gattii. *Journal of Fungi (Basel, Switzerland)*, **2022**, 8, 430	5.6	0
16	Future strategies for the treatment of cryptococcal meningoencephalitis in pediatric patients. *Expert Opinion on Orphan Drugs*, **2014**, 2, 245-257	1.1	
15	Retrospective review of amphotericin B use in a tertiary-care medical center. *American Journal of Health-System Pharmacy*, **1987**, 44, 1353-1357	2.2	
14	168. Efficacy of the Novel gwt1 Inhibitor APX2039 in a Rabbit Model of cryptococcus Meningitis. *Open Forum Infectious Diseases*, **2020**, 7, S213-S213	1	
13	Management of phaeohyphomycosis **2019**, 337-345		
12	Management of endemic mycoses **2019**, 317-323		
11	Management of mucormycoses **2019**, 357-362		
10	Management of cryptococcosis **2019**, 301-315		
9	Management of Cryptococcal Meningoencephalitis in Both Developed and Developing Countries565-584		
8	The Interaction of Cryptococcus neoformans with Host MacroPhages and Neutrophils371-385		
7	Pulmonary Innate and Adaptive Defenses against Cryptococcus451-464		
6	Physical Defenses and Nonspecific Immunity177-222		
5	Tissue Responses and Special Topics in Immunity271-324		
4	Virulence Mechanisms of Cryptococcus gattii: Convergence and Divergence189-201		
3	G-Protein Signaling Pathways: Regulating Morphogenesis and Virulence of Cryptococcus151-165		
2	Acquired Humoral Immunity to Cryptococcus neoformans397-408		

1 Fungal Infections of the Central Nervous System **2021**, 803-819